ALDER BIOPHARMACEUTICALS INC's ticker is ALDR and the CUSIP is 014339105. A total of 157 filers reported holding ALDER BIOPHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 3.13 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2018 | $3,697,000 | -83.6% | 291,120 | -85.2% | 0.01% | -84.5% |
Q4 2017 | $22,505,000 | +11.3% | 1,965,471 | +19.1% | 0.06% | +1.8% |
Q3 2017 | $20,219,000 | +106.4% | 1,650,540 | +159.4% | 0.06% | +90.0% |
Q2 2017 | $9,798,000 | -23.0% | 636,250 | +4.0% | 0.03% | -26.8% |
Q1 2017 | $12,724,000 | +69.7% | 611,706 | +69.7% | 0.04% | +46.4% |
Q4 2016 | $7,498,000 | +18.8% | 360,457 | +87.1% | 0.03% | +16.7% |
Q3 2016 | $6,313,000 | -51.5% | 192,636 | -55.5% | 0.02% | -52.9% |
Q2 2016 | $13,022,000 | +759.5% | 433,054 | +442.7% | 0.05% | +628.6% |
Q1 2016 | $1,515,000 | -24.1% | 79,800 | +32.1% | 0.01% | -12.5% |
Q4 2015 | $1,995,000 | +31.2% | 60,400 | +30.2% | 0.01% | +14.3% |
Q3 2015 | $1,520,000 | -25.7% | 46,400 | +5.2% | 0.01% | -12.5% |
Q2 2015 | $2,047,000 | +28.0% | 44,100 | -29.7% | 0.01% | +14.3% |
Q1 2015 | $1,599,000 | – | 62,700 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management III, LLC | 2,942,130 | $34,629,000 | 11.36% |
Foresite Capital Management II, LLC | 1,586,220 | $18,670,000 | 10.50% |
DAFNA Capital Management LLC | 636,013 | $7,486,000 | 2.81% |
Redmile Group, LLC | 8,244,896 | $97,042,000 | 2.75% |
Lion Point Capital, LP | 1,204,600 | $14,178,000 | 1.40% |
Palo Alto Investors LP | 1,861,630 | $21,911,000 | 1.06% |
SAMLYN CAPITAL, LLC | 3,517,856 | $41,405,000 | 0.87% |
Bellevue Group AG | 4,118,806 | $48,478,000 | 0.83% |
Rock Springs Capital Management LP | 1,562,300 | $18,388,000 | 0.66% |
Artal Group S.A. | 850,000 | $10,005,000 | 0.40% |